NF-κB in Thyroid Cancer: An Update

Int J Mol Sci. 2024 Oct 25;25(21):11464. doi: 10.3390/ijms252111464.

Abstract

The dysregulated NF-κB basal activity is a common feature of human thyroid carcinomas, especially in poorly differentiated or undifferentiated forms that, even if rare, are often resistant to standard therapies, and, therefore, are uncurable. Despite the molecular mechanisms leading to NF-κB activation in thyroid cancer being only partially understood, during the last few years, it has become clear that NF-κB contributes in different ways to the oncogenic potential of thyroid neoplastic cells. Indeed, it enhances their proliferation and viability, promotes their migration to and colonization of distant organs, and fuels their microenvironment. In addition, NF-κB signaling plays an important role in cancer stem cells from more aggressive thyroid carcinomas. Interfering with the different upstream and/or downstream pathways that drive NF-κB activity in thyroid neoplastic cells is an attractive strategy for the development of novel therapeutic drugs capable of overcoming the therapy resistance of advanced thyroid carcinomas. This review focuses on the recent findings about the key functions of NF-κB in thyroid cancer and discusses the potential implications of targeting NF-κB in advanced thyroid carcinomas.

Keywords: NF-κB; target genes; thyroid cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Gene Expression Regulation, Neoplastic
  • Humans
  • NF-kappa B* / metabolism
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology
  • Signal Transduction*
  • Thyroid Neoplasms* / metabolism
  • Thyroid Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • NF-kappa B

Grants and funding

This work is supported by Unione europea-Next Generation EU, Piano Nazionale di Ripresa e Resilienza (PNRR)—Missione 4 “Istruzione e Ricerca”—Componente C2—Investimento 1.1—Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale (PRIN), project ID. 202284LP94, CUP number B53D23021210006, and project ID 2022LTJTNCW, CUP number E53D23009950006.